Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22508798 | 0.81 | TRPV3 (0.39) | DAOHTTALDH1A1MAPTL3MBTL1 | |
| SCHEMBL16105820 | 0.79 | DAO (0.55) | DAOHTTALDH1A1TRPV3 | |
| SCHEMBL12436729 | 0.79 | ALDH1A1 (0.45) | DAOHTTALDH1A1MAPTL3MBTL1 | |
| SCHEMBL21050994 | 0.76 | ALDH1A1 (0.43) | DAOHTTALDH1A1MAPTL3MBTL1 | |
| SCHEMBL27959406 | 0.76 | IGF1R (0.37) | DAOHTTALDH1A1TRPV3 | |
| SCHEMBL30986331 | 0.76 | ALDH1A1 (0.52) | DAOHTTALDH1A1MAPTTRPV3 | |
| SCHEMBL1238835 | 0.76 | ALDH1A1 (0.52) | DAOHTTALDH1A1MAPTTRPV3 | |
| SCHEMBL1528912 | 0.75 | DAO (0.45) | DAOHTTALDH1A1 | |
| SCHEMBL31634160 | 0.74 | GRIK1 (0.56) | DPP4 | |
| SCHEMBL27959441 | 0.74 | IGF1R (0.36) | DAOHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842705-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | EMORY UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| US-7371766-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2004-09-09 | — | — | US | disclosed |
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | disclosed |
| EP-1242379-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | Emory University (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040188-A9 | CURCUMIN ANALOGUES FOR TREATING CANCER | UNIV EMORY (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2002-02-14 | — | — | US | disclosed |
| WO-2001040188-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | EMORY UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | STAT3 458/4885DAO 4442/4885ADRB2 2702/4885 |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | PGF, VEGFA, VHL | STAT3 458/4885DAO 4442/4885ADRB2 2702/4885 |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | STAT3 458/4885DAO 4442/4885ADRB2 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.